New agents in the therapy of hormone-refractory patients with prostate cancer

Semin Oncol. 1995 Feb;22(1 Suppl 1):32-4.
No abstract available

Publication types

  • Review

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bone Neoplasms / secondary
  • Humans
  • Male
  • Mitoxantrone / administration & dosage
  • Prostate-Specific Antigen / analysis
  • Prostatic Neoplasms / diagnosis
  • Prostatic Neoplasms / drug therapy*
  • Prostatic Neoplasms / mortality
  • Prostatic Neoplasms / pathology
  • Quality of Life
  • Suramin / administration & dosage
  • Survival Analysis

Substances

  • Suramin
  • Mitoxantrone
  • Prostate-Specific Antigen